OrbiMed Secures $3 Billion for Global and Asian Private Equity Funds
OrbiMed, a prominent figure in the global healthcare investment landscape, has recently announced a significant achievement: securing commitments totaling $3 billion for two newly established private equity funds. These funds, named OrbiMed Private Investments X and OrbiMed Asia Partners VI, aim to harness the vast opportunities within the healthcare sector across various regions.
OrbiMed Private Investments X has successfully attracted over $1.9 billion, with a focus on capitalizing on venture capital opportunities in the biomedical field in the United States and Europe. This sector is characterized by groundbreaking advancements and an ever-evolving landscape, making it an exciting area for investment. Meanwhile, OrbiMed Asia Partners VI has garnered more than $1 billion, targeting growth and venture capital opportunities in the flourishing healthcare markets throughout Asia. Both funds are committed to fostering the development of leading healthcare enterprises that specialize in biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services.
Reflecting on this significant milestone, Carl Gordon, managing partner at OrbiMed, remarked, "There has never been a more thrilling time to invest in innovations within the life sciences. The rise of AI, the increasing diversity of new therapeutic approaches, and China's emergence as a leading force in biotechnology present novel opportunities for the development of transformative therapies. We look forward to supporting entrepreneurs in building top-tier healthcare companies leveraging these advancements."
OrbiMed's operations are backed by a robust framework of leadership, comprising 20 partners and a team of over 150 professionals with complementary skill sets in corporate development, strategy, business operations, and finance. The firm has established a presence in key healthcare markets worldwide, with offices located in major cities including New York, London, San Francisco, Shanghai, Hong Kong, and Mumbai.
The investor base for these new funds includes a diverse array of institutional participants, from medical institutions and university endowments to charitable foundations, pension funds, sovereign wealth funds, and family offices. This diverse support reflects the confidence investors have in OrbiMed’s vision for the future of healthcare.
Carter Neild, also a managing partner at OrbiMed, expressed gratitude for the continued backing of their longstanding investors. He stated, "We are thankful for the ongoing support from our many long-term investors. We will work tirelessly to meet their high expectations in the years to come."
OrbiMed's commitment to advancing healthcare innovation is driven by its strategic goal of being the preferred capital provider in the sector. With over $21 billion in assets under management, OrbiMed invests across the healthcare spectrum, spanning from startups to large multinational corporations. Their approach incorporates private equity funds, publicly traded equity funds, as well as royalty and credit funds.
In today’s dynamic investment climate, OrbiMed stands out by providing tailored financing solutions bolstered by the extensive resources of its global team. This comprehensive support structure is designed to enhance the growth potential of premier healthcare companies. As OrbiMed embarks on this new chapter with its recently raised funds, it reinforces its commitment to driving meaningful advancements in healthcare through smart investment strategies and partnerships geared towards fostering innovation and improving patient outcomes globally.
To stay updated on their latest ventures and insights into the healthcare investment landscape, visit their website at www.orbimed.com.
OrbiMed Private Investments X has successfully attracted over $1.9 billion, with a focus on capitalizing on venture capital opportunities in the biomedical field in the United States and Europe. This sector is characterized by groundbreaking advancements and an ever-evolving landscape, making it an exciting area for investment. Meanwhile, OrbiMed Asia Partners VI has garnered more than $1 billion, targeting growth and venture capital opportunities in the flourishing healthcare markets throughout Asia. Both funds are committed to fostering the development of leading healthcare enterprises that specialize in biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services.
Reflecting on this significant milestone, Carl Gordon, managing partner at OrbiMed, remarked, "There has never been a more thrilling time to invest in innovations within the life sciences. The rise of AI, the increasing diversity of new therapeutic approaches, and China's emergence as a leading force in biotechnology present novel opportunities for the development of transformative therapies. We look forward to supporting entrepreneurs in building top-tier healthcare companies leveraging these advancements."
OrbiMed's operations are backed by a robust framework of leadership, comprising 20 partners and a team of over 150 professionals with complementary skill sets in corporate development, strategy, business operations, and finance. The firm has established a presence in key healthcare markets worldwide, with offices located in major cities including New York, London, San Francisco, Shanghai, Hong Kong, and Mumbai.
The investor base for these new funds includes a diverse array of institutional participants, from medical institutions and university endowments to charitable foundations, pension funds, sovereign wealth funds, and family offices. This diverse support reflects the confidence investors have in OrbiMed’s vision for the future of healthcare.
Carter Neild, also a managing partner at OrbiMed, expressed gratitude for the continued backing of their longstanding investors. He stated, "We are thankful for the ongoing support from our many long-term investors. We will work tirelessly to meet their high expectations in the years to come."
OrbiMed's commitment to advancing healthcare innovation is driven by its strategic goal of being the preferred capital provider in the sector. With over $21 billion in assets under management, OrbiMed invests across the healthcare spectrum, spanning from startups to large multinational corporations. Their approach incorporates private equity funds, publicly traded equity funds, as well as royalty and credit funds.
In today’s dynamic investment climate, OrbiMed stands out by providing tailored financing solutions bolstered by the extensive resources of its global team. This comprehensive support structure is designed to enhance the growth potential of premier healthcare companies. As OrbiMed embarks on this new chapter with its recently raised funds, it reinforces its commitment to driving meaningful advancements in healthcare through smart investment strategies and partnerships geared towards fostering innovation and improving patient outcomes globally.
To stay updated on their latest ventures and insights into the healthcare investment landscape, visit their website at www.orbimed.com.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.